HTD-1801 Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving HTD-1801 Growth

• Positive Phase III data in Type 2 Diabetes significantly de-risks commercialization

In April 2025, HighTide Therapeutics announced that HTD-1801 met the primary and gated secondary endpoints in two Phase III trials (SYMPHONY 1 and 2) in Chinese patients with T2DM. The company stated it plans to submit an NDA to China’s NMPA in 2025. Successful Phase III completion substantially improves approval probability and positions HTD-1801 for potential near-term commercialization in the large Chinese diabetes market.

• Dual metabolic and liver benefits differentiate HTD-1801 from standard diabetes therapies

HTD-1801 combines berberine and ursodeoxycholic acid into a novel ionic salt with dual mechanisms involving AMPK activation and NLRP3 inflammasome inhibition. Clinical studies demonstrated improvements not only in glycemic control but also liver fat reduction, liver enzymes, lipids, and body weight. This broad-spectrum activity could make HTD-1801 particularly attractive for patients with both T2DM and MASH, a rapidly growing comorbidity population.

• Promising efficacy in MASH/NASH supports expansion into a high-value liver disease market

In a placebo-controlled Phase II study involving 100 patients with presumed MASH and T2DM, HTD-1801 achieved significant liver fat reduction versus placebo. Patients receiving 1000 mg BID showed a mean absolute liver fat reduction of -4.8% compared with -2.0% for placebo (p=0.011). A later secondary analysis published in 2025 showed that 52% of HTD-1801-treated patients achieved MRI response criteria associated with histologic improvement versus 24% of placebo-treated patients. These findings support its potential as a disease-modifying MASH therapy.

• Large addressable patient populations in T2DM and MASH create major commercial opportunity

T2DM affects more than 500 million people globally, while MASH prevalence continues to rise alongside obesity and metabolic syndrome. Importantly, a substantial proportion of MASH patients also have T2DM, creating a highly synergistic commercial opportunity for a therapy addressing both metabolic dysfunction and liver disease. Because HTD-1801 is oral and potentially lower cost than injectable incretin therapies, it may gain traction in earlier-line treatment settings and emerging markets.

• Oral administration may improve accessibility and combination use potential

Unlike injectable GLP-1 therapies, HTD-1801 is an oral small-molecule therapy, which could improve patient convenience, physician adoption, and payer acceptance. The oral route also makes it attractive for combination regimens with GLP-1 receptor agonists or SGLT2 inhibitors, particularly in patients requiring multi-target metabolic management. This positioning may help HTD-1801 remain competitive even as incretin-based therapies dominate the metabolic disease market.

HTD-1801 Recent Developments

In March 2026, HighTide Therapeutics announced that the National Medical Products Administration (NMPA) of China accepted the New Drug Application (NDA) for HTD1801 for the treatment of Type 2 Diabetes Mellitus (T2DM). This marks the first NDA submitted by HighTide Therapeutics and a major milestone on its path towards product commercialization.

In December 2025, HighTide Therapeutics reported positive topline results from its Phase III HARMONY trial, demonstrating that HTD1801 achieved the primary endpoint of this trial, with superior improvements in key cardiometabolic markers in patients with type 2 diabetes mellitus (T2DM) compared to dapagliflozin.  
“HTD-1801 Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of HTD-1801 for potential indication like Type 2 diabetes mellitus, Hypercholesterolaemia, Non-alcoholic steatohepatitis, Primary biliary cirrhosis, and Primary sclerosing cholangitis in the 7MM. A detailed picture of HTD-1801’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the HTD-1801 for potential indications. The HTD-1801 market report provides insights about HTD-1801’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current HTD-1801 performance, future market assessments inclusive of the HTD-1801 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of HTD-1801 sales forecasts, along with factors driving its market.

HTD-1801 Drug Summary

HTD-1801 (berberine ursodeoxycholate) is an orally administered, first-in-class anti-inflammatory metabolic modulator being developed by HighTide Therapeutics for the treatment of metabolic and liver diseases, including type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated steatohepatitis (MASH/NASH), primary sclerosing cholangitis (PSC), and severe hypertriglyceridemia. HTD-1801 is a novel ionic salt composed of berberine and ursodeoxycholic acid (UDCA), designed to combine the metabolic, anti-inflammatory, and hepatoprotective properties of both molecules into a single therapeutic agent. The drug exerts its effects through dual mechanisms involving AMP-activated protein kinase (AMPK) activation and NLRP3 inflammasome inhibition, leading to improvements in glucose metabolism, insulin resistance, lipid profiles, hepatic inflammation, fibrosis, and gut microbiome balance. Clinical studies have demonstrated favorable effects on HbA1c, LDL cholesterol, liver enzymes, inflammatory biomarkers, and liver fat reduction, with generally manageable gastrointestinal adverse events. HTD-1801 has shown positive Phase II and Phase III outcomes in T2DM and liver disease studies, and its New Drug Application (NDA) for T2DM has been accepted by China’s National Medical Products Administration (NMPA), highlighting its potential as a multi-target therapy for cardiovascular-kidney-metabolic diseases. The report provides HTD-1801’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the HTD-1801 Market Report

The report provides insights into:

• A comprehensive product overview including the HTD-1801 MoA, description, dosage and administration, research and development activities in potential indication like Type 2 diabetes mellitus, Hypercholesterolaemia, Non-alcoholic steatohepatitis, Primary biliary cirrhosis, and Primary sclerosing cholangitis.
• Elaborated details on HTD-1801 regulatory milestones and other development activities have been provided in HTD-1801 market report.
• The report also highlights HTD-1801‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The HTD-1801 market report also covers the patents information, generic entry and impact on cost cut.
• The HTD-1801 market report contains current and forecasted HTD-1801 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The HTD-1801 market report also features the SWOT analysis with analyst views for HTD-1801 in potential indications.

Methodology

The HTD-1801 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

HTD-1801 Analytical Perspective

• In-depth HTD-1801 Market Assessment

This HTD-1801 sales market forecast report provides a detailed market assessment of HTD-1801 for potential indication like Type 2 diabetes mellitus, Hypercholesterolaemia, Non-alcoholic steatohepatitis, Primary biliary cirrhosis, and Primary sclerosing cholangitis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted HTD-1801 sales data uptil 2034.

• HTD-1801 Clinical Assessment

The HTD-1801 market report provides the clinical trials information of HTD-1801 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

HTD-1801 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

HTD-1801 Market Potential & Revenue Forecast

• Projected market size for the HTD-1801 and its key indications
• Estimated HTD-1801 sales potential (HTD-1801 peak sales forecasts)
• HTD-1801 Pricing strategies and reimbursement landscape

HTD-1801 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• HTD-1801 Market positioning compared to existing treatments
• HTD-1801 Strengths & weaknesses relative to competitors

HTD-1801 Regulatory & Commercial Milestones

• HTD-1801 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

HTD-1801 Clinical Differentiation

• HTD-1801 Efficacy & safety advantages over existing drugs
• HTD-1801 Unique selling points

HTD-1801 Market Report Highlights

• In the coming years, the HTD-1801 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The HTD-1801 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence HTD-1801’s dominance.
• Other emerging products for Type 2 diabetes mellitus, Hypercholesterolaemia, Non-alcoholic steatohepatitis, Primary biliary cirrhosis, and Primary sclerosing cholangitis are expected to give tough market competition to HTD-1801 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of HTD-1801 in potential indications.
• Analyse HTD-1801 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted HTD-1801 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of HTD-1801 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of HTD-1801? How strong is HTD-1801’s clinical and commercial performance?
• What is HTD-1801’s clinical trial status in each individual indications such as Type 2 diabetes mellitus, Hypercholesterolaemia, Non-alcoholic steatohepatitis, Primary biliary cirrhosis, and Primary sclerosing cholangitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HTD-1801 Manufacturers?
• What are the key designations that have been granted to HTD-1801 for potential indications? How are they going to impact HTD-1801’s penetration in various geographies?
• What is the current and forecasted HTD-1801 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of HTD-1801 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to HTD-1801 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is HTD-1801? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.